drugset / Trial / NCT05574543
A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The objectives of the study are to evaluate the safety and preliminary efficacy of a single administration of AGA111 for lumbar interbody fusion in patients with degenerative disc disease.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2022-07-13
- Completion
- 2022-07-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGA111 | Unknown | 0.25 mg | Other |
| Subject | AGA111 | Unknown | 0.5 mg | Other |